TNFRSF17 and AL amyloidosis: In a study by Bal S. et al., patients with AL amyloidosis at Memorial Sloan Kettering Cancer Center from 2012 to 2018 were assessed for BCMA, GPRC5D, and BCL2 expression in bone marrow amyloidogenic plasma cells (52).